1	As	_	IN	_	_	14	ADV	_	_
2	Georgia-Pacific	_	NNP	_	_	4	NMOD	_	_
3	's	_	POS	_	_	2	SUFFIX	_	_
4	bid	_	NN	_	_	9	SBJ	_	_
5	for	_	IN	_	_	4	NMOD	_	_
6	Great	_	NNP	_	_	8	NAME	_	_
7	Northern	_	NNP	_	_	8	NAME	_	_
8	Nekoosa	_	NNP	_	_	5	PMOD	_	_
9	has	_	VBZ	_	_	1	SUB	_	_
10	shown	_	VBN	_	_	9	VC	_	_
11	,	_	,	_	_	14	P	_	_
12	uninvited	_	JJ	_	_	13	NMOD	_	_
13	takeovers	_	NNS	_	_	14	SBJ	_	_
14	are	_	VBP	_	_	0	ROOT	_	_
15	still	_	RB	_	_	14	ADV	_	_
16	alive	_	JJ	_	_	14	PRD	_	_
17	despite	_	IN	_	_	14	ADV	_	_
18	premature	_	JJ	_	_	19	NMOD	_	_
19	reports	_	NNS	_	_	17	PMOD	_	_
20	of	_	IN	_	_	19	NMOD	_	_
21	their	_	PRP$	_	_	22	NMOD	_	_
22	demise	_	NN	_	_	20	PMOD	_	_
23	.	_	.	_	_	14	P	_	_

1	Therefore	_	RB	_	_	8	ADV	_	_
2	,	_	,	_	_	8	P	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	debate	_	NN	_	_	8	SBJ	_	_
5	about	_	IN	_	_	4	NMOD	_	_
6	poison	_	NN	_	_	7	NMOD	_	_
7	pills	_	NNS	_	_	5	PMOD	_	_
8	will	_	MD	_	_	0	ROOT	_	_
9	continue	_	VB	_	_	8	VC	_	_
10	to	_	TO	_	_	9	OPRD	_	_
11	rage	_	VB	_	_	10	IM	_	_
12	in	_	IN	_	_	11	LOC	_	_
13	the	_	DT	_	_	14	NMOD	_	_
14	boardrooms	_	NNS	_	_	12	PMOD	_	_
15	of	_	IN	_	_	14	NMOD	_	_
16	corporations	_	NNS	_	_	15	PMOD	_	_
17	and	_	CC	_	_	14	COORD	_	_
18	the	_	DT	_	_	19	NMOD	_	_
19	halls	_	NNS	_	_	17	CONJ	_	_
20	of	_	IN	_	_	19	NMOD	_	_
21	academia	_	NN	_	_	20	PMOD	_	_
22	.	_	.	_	_	8	P	_	_

1	Although	_	IN	_	_	13	ADV	_	_
2	poison	_	NN	_	_	3	NMOD	_	_
3	pills	_	NNS	_	_	4	SBJ	_	_
4	come	_	VBP	_	_	1	SUB	_	_
5	in	_	IN	_	_	4	MNR	_	_
6	different	_	JJ	_	_	7	NMOD	_	_
7	colors	_	NNS	_	_	5	PMOD	_	_
8	and	_	CC	_	_	7	COORD	_	_
9	shapes	_	NNS	_	_	8	CONJ	_	_
10	,	_	,	_	_	13	P	_	_
11	they	_	PRP	_	_	13	SBJ	_	_
12	usually	_	RB	_	_	13	TMP	_	_
13	give	_	VBP	_	_	0	ROOT	_	_
14	current	_	JJ	_	_	15	NMOD	_	_
15	shareholders	_	NNS	_	_	13	OBJ	_	_
16	the	_	DT	_	_	17	NMOD	_	_
17	right	_	NN	_	_	13	OBJ	_	_
18	to	_	TO	_	_	17	NMOD	_	_
19	buy	_	VB	_	_	18	IM	_	_
20	more	_	JJR	_	_	21	NMOD	_	_
21	stock	_	NN	_	_	19	OBJ	_	_
22	of	_	IN	_	_	21	NMOD	_	_
23	their	_	PRP$	_	_	24	NMOD	_	_
24	corporation	_	NN	_	_	22	PMOD	_	_
25	at	_	IN	_	_	19	ADV	_	_
26	a	_	DT	_	_	28	NMOD	_	_
27	large	_	JJ	_	_	28	NMOD	_	_
28	discount	_	NN	_	_	25	PMOD	_	_
29	if	_	IN	_	_	19	ADV	_	_
30	certain	_	JJ	_	_	31	NMOD	_	_
31	events	_	NNS	_	_	32	SBJ	_	_
32	occur	_	VBP	_	_	29	SUB	_	_
33	--	_	:	_	_	29	P	_	_
34	typically	_	RB	_	_	36	DEP	_	_
35	,	_	,	_	_	36	P	_	_
36	if	_	IN	_	_	29	PRN	_	_
37	a	_	DT	_	_	39	NMOD	_	_
38	hostile	_	JJ	_	_	39	NMOD	_	_
39	bidder	_	NN	_	_	40	SBJ	_	_
40	acquires	_	VBZ	_	_	36	SUB	_	_
41	more	_	JJR	_	_	40	OBJ	_	_
42	than	_	IN	_	_	41	NMOD	_	_
43	a	_	DT	_	_	45	NMOD	_	_
44	specified	_	JJ	_	_	45	NMOD	_	_
45	percentage	_	NN	_	_	42	PMOD	_	_
46	of	_	IN	_	_	45	NMOD	_	_
47	the	_	DT	_	_	48	NMOD	_	_
48	corporation	_	NN	_	_	50	NMOD	_	_
49	's	_	POS	_	_	48	SUFFIX	_	_
50	stock	_	NN	_	_	46	PMOD	_	_
51	.	_	.	_	_	13	P	_	_

1	However	_	RB	_	_	7	ADV	_	_
2	,	_	,	_	_	7	P	_	_
3	these	_	DT	_	_	6	NMOD	_	_
4	discount	_	NN	_	_	6	NMOD	_	_
5	purchase	_	NN	_	_	6	NMOD	_	_
6	rights	_	NNS	_	_	7	SBJ	_	_
7	may	_	MD	_	_	0	ROOT	_	_
8	generally	_	RB	_	_	7	ADV	_	_
9	be	_	VB	_	_	7	VC	_	_
10	redeemed	_	VBN	_	_	9	VC	_	_
11	at	_	IN	_	_	10	ADV	_	_
12	a	_	DT	_	_	14	NMOD	_	_
13	nominal	_	JJ	_	_	14	NMOD	_	_
14	cost	_	NN	_	_	11	PMOD	_	_
15	by	_	IN	_	_	10	LGS	_	_
16	the	_	DT	_	_	17	NMOD	_	_
17	corporation	_	NN	_	_	19	NMOD	_	_
18	's	_	POS	_	_	17	SUFFIX	_	_
19	directors	_	NNS	_	_	15	PMOD	_	_
20	if	_	IN	_	_	10	ADV	_	_
21	they	_	PRP	_	_	22	SBJ	_	_
22	approve	_	VBP	_	_	20	SUB	_	_
23	of	_	IN	_	_	22	ADV	_	_
24	a	_	DT	_	_	25	NMOD	_	_
25	bidder	_	NN	_	_	23	PMOD	_	_
26	.	_	.	_	_	7	P	_	_

1	Supporters	_	NNS	_	_	5	SBJ	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	poison	_	NN	_	_	4	NMOD	_	_
4	pills	_	NNS	_	_	2	PMOD	_	_
5	argue	_	VBP	_	_	0	ROOT	_	_
6	that	_	DT	_	_	5	OBJ	_	_
7	their	_	PRP$	_	_	8	NMOD	_	_
8	adoption	_	NN	_	_	9	SBJ	_	_
9	forces	_	VBZ	_	_	6	SUB	_	_
10	bidders	_	NNS	_	_	9	OBJ	_	_
11	to	_	TO	_	_	9	OPRD	_	_
12	negotiate	_	VB	_	_	11	IM	_	_
13	with	_	IN	_	_	12	ADV	_	_
14	a	_	DT	_	_	15	NMOD	_	_
15	corporation	_	NN	_	_	17	NMOD	_	_
16	's	_	POS	_	_	15	SUFFIX	_	_
17	directors	_	NNS	_	_	13	PMOD	_	_
18	,	_	,	_	_	17	P	_	_
19	who	_	WP	_	_	20	SBJ	_	_
20	are	_	VBP	_	_	17	NMOD	_	_
21	thereby	_	RB	_	_	20	ADV	_	_
22	put	_	VBN	_	_	20	VC	_	_
23	in	_	IN	_	_	22	PUT	_	_
24	a	_	DT	_	_	26	NMOD	_	_
25	better	_	JJR	_	_	26	NMOD	_	_
26	position	_	NN	_	_	23	PMOD	_	_
27	to	_	TO	_	_	26	NMOD	_	_
28	pursue	_	VB	_	_	27	IM	_	_
29	the	_	DT	_	_	31	NMOD	_	_
30	long-term	_	JJ	_	_	31	NMOD	_	_
31	interests	_	NNS	_	_	28	OBJ	_	_
32	of	_	IN	_	_	31	NMOD	_	_
33	the	_	DT	_	_	34	NMOD	_	_
34	corporation	_	NN	_	_	32	PMOD	_	_
35	.	_	.	_	_	5	P	_	_

1	Recent	_	JJ	_	_	2	NMOD	_	_
2	studies	_	NNS	_	_	7	SBJ	_	_
3	by	_	IN	_	_	2	NMOD	_	_
4	Georgeson	_	NNP	_	_	3	PMOD	_	_
5	&	_	CC	_	_	4	COORD	_	_
6	Co.	_	NNP	_	_	5	CONJ	_	_
7	conclude	_	VBP	_	_	0	ROOT	_	_
8	that	_	IN	_	_	7	OBJ	_	_
9	corporations	_	NNS	_	_	13	SBJ	_	_
10	with	_	IN	_	_	9	NMOD	_	_
11	poison	_	NN	_	_	12	NMOD	_	_
12	pills	_	NNS	_	_	10	PMOD	_	_
13	have	_	VBP	_	_	8	SUB	_	_
14	experienced	_	VBN	_	_	13	VC	_	_
15	greater	_	JJR	_	_	17	NMOD	_	_
16	stock-price	_	JJ	_	_	17	NMOD	_	_
17	appreciation	_	NN	_	_	14	OBJ	_	_
18	than	_	IN	_	_	17	NMOD	_	_
19	corporations	_	NNS	_	_	18	PMOD	_	_
20	without	_	IN	_	_	19	NMOD	_	_
21	poison	_	NN	_	_	22	NMOD	_	_
22	pills	_	NNS	_	_	20	PMOD	_	_
23	during	_	IN	_	_	14	TMP	_	_
24	the	_	DT	_	_	27	NMOD	_	_
25	past	_	JJ	_	_	27	NMOD	_	_
26	few	_	JJ	_	_	27	NMOD	_	_
27	years	_	NNS	_	_	23	PMOD	_	_
28	.	_	.	_	_	7	P	_	_

1	Critics	_	NNS	_	_	5	SBJ	_	_
2	of	_	IN	_	_	1	NMOD	_	_
3	poison	_	NN	_	_	4	NMOD	_	_
4	pills	_	NNS	_	_	2	PMOD	_	_
5	argue	_	VBP	_	_	0	ROOT	_	_
6	that	_	IN	_	_	5	OBJ	_	_
7	they	_	PRP	_	_	8	SBJ	_	_
8	harm	_	VBP	_	_	6	SUB	_	_
9	shareholders	_	NNS	_	_	8	OBJ	_	_
10	by	_	IN	_	_	8	MNR	_	_
11	letting	_	VBG	_	_	10	PMOD	_	_
12	corporate	_	JJ	_	_	13	NMOD	_	_
13	management	_	NN	_	_	11	OBJ	_	_
14	defeat	_	VB	_	_	11	OPRD	_	_
15	takeover	_	NN	_	_	16	NMOD	_	_
16	bids	_	NNS	_	_	14	OBJ	_	_
17	at	_	IN	_	_	16	NMOD	_	_
18	premium	_	JJ	_	_	19	NMOD	_	_
19	prices	_	NNS	_	_	17	PMOD	_	_
20	and	_	CC	_	_	10	COORD	_	_
21	by	_	IN	_	_	20	CONJ	_	_
22	deterring	_	VBG	_	_	21	PMOD	_	_
23	premium	_	JJ	_	_	24	NMOD	_	_
24	bids	_	NNS	_	_	22	OBJ	_	_
25	from	_	IN	_	_	22	ADV	_	_
26	ever	_	RB	_	_	27	TMP	_	_
27	being	_	VBG	_	_	25	PMOD	_	_
28	made	_	VBN	_	_	27	VC	_	_
29	to	_	TO	_	_	28	DTV	_	_
30	shareholders	_	NNS	_	_	29	PMOD	_	_
31	.	_	.	_	_	5	P	_	_

1	These	_	DT	_	_	2	NMOD	_	_
2	critics	_	NNS	_	_	3	SBJ	_	_
3	are	_	VBP	_	_	0	ROOT	_	_
4	backed	_	VBN	_	_	3	VC	_	_
5	by	_	IN	_	_	4	LGS	_	_
6	several	_	JJ	_	_	8	NMOD	_	_
7	academic	_	JJ	_	_	8	NMOD	_	_
8	studies	_	NNS	_	_	5	PMOD	_	_
9	showing	_	VBG	_	_	8	APPO	_	_
10	that	_	IN	_	_	9	OBJ	_	_
11	the	_	DT	_	_	12	NMOD	_	_
12	adoption	_	NN	_	_	16	SBJ	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	poison	_	NN	_	_	15	NMOD	_	_
15	pills	_	NNS	_	_	13	PMOD	_	_
16	reduces	_	VBZ	_	_	10	SUB	_	_
17	shareholder	_	NN	_	_	18	NMOD	_	_
18	values	_	NNS	_	_	16	OBJ	_	_
19	not	_	RB	_	_	16	TMP	_	_
20	merely	_	RB	_	_	19	DEP	_	_
21	in	_	IN	_	_	19	COORD	_	_
22	the	_	DT	_	_	24	NMOD	_	_
23	short	_	JJ	_	_	24	NMOD	_	_
24	run	_	NN	_	_	21	PMOD	_	_
25	,	_	,	_	_	21	P	_	_
26	but	_	CC	_	_	21	COORD	_	_
27	also	_	RB	_	_	26	COORD	_	_
28	over	_	IN	_	_	26	CONJ	_	_
29	longer	_	JJR	_	_	30	NMOD	_	_
30	periods	_	NNS	_	_	28	PMOD	_	_
31	.	_	.	_	_	3	P	_	_

1	Institutional	_	JJ	_	_	2	NMOD	_	_
2	investors	_	NNS	_	_	12	SBJ	_	_
3	that	_	WDT	_	_	4	SBJ	_	_
4	must	_	MD	_	_	2	NMOD	_	_
5	evaluate	_	VB	_	_	4	VC	_	_
6	poison	_	NN	_	_	7	NMOD	_	_
7	pills	_	NNS	_	_	5	OBJ	_	_
8	on	_	IN	_	_	5	TMP	_	_
9	a	_	DT	_	_	11	NMOD	_	_
10	regular	_	JJ	_	_	11	NMOD	_	_
11	basis	_	NN	_	_	8	PMOD	_	_
12	are	_	VBP	_	_	0	ROOT	_	_
13	interested	_	JJ	_	_	12	VC	_	_
14	less	_	RBR	_	_	13	ADV	_	_
15	in	_	IN	_	_	13	ADV	_	_
16	this	_	DT	_	_	18	NMOD	_	_
17	general	_	JJ	_	_	18	NMOD	_	_
18	debate	_	NN	_	_	15	PMOD	_	_
19	than	_	IN	_	_	14	AMOD	_	_
20	in	_	IN	_	_	19	PMOD	_	_
21	the	_	DT	_	_	22	NMOD	_	_
22	answers	_	NNS	_	_	20	PMOD	_	_
23	to	_	TO	_	_	22	NMOD	_	_
24	specific	_	JJ	_	_	25	NMOD	_	_
25	questions	_	NNS	_	_	23	PMOD	_	_
26	about	_	IN	_	_	25	NMOD	_	_
27	the	_	DT	_	_	28	NMOD	_	_
28	corporation	_	NN	_	_	26	PMOD	_	_
29	issuing	_	VBG	_	_	28	APPO	_	_
30	the	_	DT	_	_	31	NMOD	_	_
31	pill	_	NN	_	_	29	OBJ	_	_
32	.	_	.	_	_	12	P	_	_

1	Does	_	VBZ	_	_	0	ROOT	_	_
2	this	_	DT	_	_	3	NMOD	_	_
3	corporation	_	NN	_	_	1	SBJ	_	_
4	have	_	VB	_	_	1	VC	_	_
5	a	_	DT	_	_	8	NMOD	_	_
6	high-quality	_	JJ	_	_	8	NMOD	_	_
7	management	_	NN	_	_	8	NMOD	_	_
8	team	_	NN	_	_	4	OBJ	_	_
9	with	_	IN	_	_	8	NMOD	_	_
10	a	_	DT	_	_	13	NMOD	_	_
11	good	_	JJ	_	_	13	NMOD	_	_
12	track	_	NN	_	_	13	NMOD	_	_
13	record	_	NN	_	_	9	PMOD	_	_
14	?	_	.	_	_	1	P	_	_

1	Does	_	VBZ	_	_	0	ROOT	_	_
2	this	_	DT	_	_	3	NMOD	_	_
3	team	_	NN	_	_	1	SBJ	_	_
4	have	_	VB	_	_	1	VC	_	_
5	a	_	DT	_	_	7	NMOD	_	_
6	viable	_	JJ	_	_	7	NMOD	_	_
7	strategy	_	NN	_	_	4	OBJ	_	_
8	for	_	IN	_	_	7	NMOD	_	_
9	improving	_	VBG	_	_	8	PMOD	_	_
10	shareholder	_	NN	_	_	11	NMOD	_	_
11	values	_	NNS	_	_	9	OBJ	_	_
12	,	_	,	_	_	1	P	_	_
13	and	_	CC	_	_	1	COORD	_	_
14	does	_	VBZ	_	_	13	CONJ	_	_
15	this	_	DT	_	_	16	NMOD	_	_
16	strategy	_	NN	_	_	14	SBJ	_	_
17	require	_	VB	_	_	14	VC	_	_
18	implementation	_	NN	_	_	17	OBJ	_	_
19	over	_	IN	_	_	17	TMP	_	_
20	an	_	DT	_	_	22	NMOD	_	_
21	extended	_	JJ	_	_	22	NMOD	_	_
22	period	_	NN	_	_	19	PMOD	_	_
23	?	_	.	_	_	1	P	_	_

1	Will	_	MD	_	_	0	ROOT	_	_
2	the	_	DT	_	_	3	NMOD	_	_
3	adoption	_	NN	_	_	1	SBJ	_	_
4	of	_	IN	_	_	3	NMOD	_	_
5	this	_	DT	_	_	7	NMOD	_	_
6	particular	_	JJ	_	_	7	NMOD	_	_
7	form	_	NN	_	_	4	PMOD	_	_
8	of	_	IN	_	_	7	NMOD	_	_
9	a	_	DT	_	_	11	NMOD	_	_
10	poison	_	NN	_	_	11	NMOD	_	_
11	pill	_	NN	_	_	8	PMOD	_	_
12	significantly	_	RB	_	_	13	MNR	_	_
13	improve	_	VB	_	_	1	VC	_	_
14	the	_	DT	_	_	15	NMOD	_	_
15	chances	_	NNS	_	_	13	OBJ	_	_
16	for	_	IN	_	_	15	NMOD	_	_
17	management	_	NN	_	_	18	SBJ	_	_
18	to	_	TO	_	_	16	SUB	_	_
19	carry	_	VB	_	_	18	IM	_	_
20	out	_	RP	_	_	19	PRT	_	_
21	this	_	DT	_	_	22	NMOD	_	_
22	strategy	_	NN	_	_	19	OBJ	_	_
23	?	_	.	_	_	1	P	_	_

1	If	_	IN	_	_	13	ADV	_	_
2	the	_	DT	_	_	3	NMOD	_	_
3	answers	_	NNS	_	_	7	SBJ	_	_
4	to	_	TO	_	_	3	NMOD	_	_
5	these	_	DT	_	_	6	NMOD	_	_
6	questions	_	NNS	_	_	4	PMOD	_	_
7	are	_	VBP	_	_	1	SUB	_	_
8	affirmative	_	JJ	_	_	7	PRD	_	_
9	,	_	,	_	_	13	P	_	_
10	then	_	RB	_	_	13	ADV	_	_
11	institutional	_	JJ	_	_	12	NMOD	_	_
12	investors	_	NNS	_	_	13	SBJ	_	_
13	are	_	VBP	_	_	0	ROOT	_	_
14	likely	_	JJ	_	_	13	PRD	_	_
15	to	_	TO	_	_	14	AMOD	_	_
16	be	_	VB	_	_	15	IM	_	_
17	favorably	_	RB	_	_	18	AMOD	_	_
18	disposed	_	JJ	_	_	16	PRD	_	_
19	toward	_	IN	_	_	18	AMOD	_	_
20	a	_	DT	_	_	23	NMOD	_	_
21	specific	_	JJ	_	_	23	NMOD	_	_
22	poison	_	NN	_	_	23	NMOD	_	_
23	pill	_	NN	_	_	19	PMOD	_	_
24	.	_	.	_	_	13	P	_	_

1	However	_	RB	_	_	5	ADV	_	_
2	,	_	,	_	_	5	P	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	problem	_	NN	_	_	5	SBJ	_	_
5	is	_	VBZ	_	_	0	ROOT	_	_
6	that	_	DT	_	_	5	PRD	_	_
7	once	_	RB	_	_	15	TMP	_	_
8	most	_	JJS	_	_	10	NMOD	_	_
9	poison	_	JJ	_	_	10	NMOD	_	_
10	pills	_	NNS	_	_	11	SBJ	_	_
11	are	_	VBP	_	_	7	SUB	_	_
12	adopted	_	VBN	_	_	11	VC	_	_
13	,	_	,	_	_	15	P	_	_
14	they	_	PRP	_	_	15	SBJ	_	_
15	survive	_	VBP	_	_	6	SUB	_	_
16	forever	_	RB	_	_	15	TMP	_	_
17	.	_	.	_	_	5	P	_	_

1	Although	_	IN	_	_	11	ADV	_	_
2	the	_	DT	_	_	5	NMOD	_	_
3	current	_	JJ	_	_	5	NMOD	_	_
4	management	_	NN	_	_	5	NMOD	_	_
5	team	_	NN	_	_	6	SBJ	_	_
6	may	_	MD	_	_	1	SUB	_	_
7	be	_	VB	_	_	6	VC	_	_
8	outstanding	_	JJ	_	_	7	PRD	_	_
9	,	_	,	_	_	11	P	_	_
10	who	_	WP	_	_	11	SBJ	_	_
11	will	_	MD	_	_	0	ROOT	_	_
12	be	_	VB	_	_	11	VC	_	_
13	the	_	DT	_	_	14	NMOD	_	_
14	CEO	_	NNP	_	_	12	PRD	_	_
15	in	_	IN	_	_	12	TMP	_	_
16	10	_	CD	_	_	17	NMOD	_	_
17	years	_	NNS	_	_	15	PMOD	_	_
18	?	_	.	_	_	11	P	_	_

1	Although	_	IN	_	_	10	ADV	_	_
2	the	_	DT	_	_	4	NMOD	_	_
3	five-year	_	JJ	_	_	4	NMOD	_	_
4	strategy	_	NN	_	_	5	SBJ	_	_
5	may	_	MD	_	_	1	SUB	_	_
6	be	_	VB	_	_	5	VC	_	_
7	excellent	_	JJ	_	_	6	PRD	_	_
8	,	_	,	_	_	10	P	_	_
9	what	_	WP	_	_	10	SBJ	_	_
10	will	_	MD	_	_	0	ROOT	_	_
11	be	_	VB	_	_	10	VC	_	_
12	the	_	DT	_	_	13	NMOD	_	_
13	strategy	_	NN	_	_	11	PRD	_	_
14	in	_	IN	_	_	11	TMP	_	_
15	25	_	CD	_	_	16	NMOD	_	_
16	years	_	NNS	_	_	14	PMOD	_	_
17	?	_	.	_	_	10	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	solution	_	NN	_	_	6	SBJ	_	_
3	to	_	TO	_	_	2	NMOD	_	_
4	this	_	DT	_	_	5	NMOD	_	_
5	problem	_	NN	_	_	3	PMOD	_	_
6	is	_	VBZ	_	_	0	ROOT	_	_
7	a	_	DT	_	_	10	NMOD	_	_
8	time-limited	_	JJ	_	_	10	NMOD	_	_
9	poison	_	NN	_	_	10	NMOD	_	_
10	pill	_	NN	_	_	6	PRD	_	_
11	.	_	.	_	_	6	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	limit	_	NN	_	_	3	SBJ	_	_
3	could	_	MD	_	_	0	ROOT	_	_
4	range	_	VB	_	_	3	VC	_	_
5	from	_	IN	_	_	4	ADV	_	_
6	three	_	CD	_	_	7	NMOD	_	_
7	years	_	NNS	_	_	5	PMOD	_	_
8	to	_	TO	_	_	5	PMOD	_	_
9	seven	_	CD	_	_	10	NMOD	_	_
10	years	_	NNS	_	_	8	PMOD	_	_
11	,	_	,	_	_	4	P	_	_
12	depending	_	VBG	_	_	4	ADV	_	_
13	on	_	IN	_	_	12	PMOD	_	_
14	the	_	DT	_	_	15	NMOD	_	_
15	composition	_	NN	_	_	13	PMOD	_	_
16	of	_	IN	_	_	15	NMOD	_	_
17	the	_	DT	_	_	19	NMOD	_	_
18	management	_	NN	_	_	19	NMOD	_	_
19	team	_	NN	_	_	16	PMOD	_	_
20	and	_	CC	_	_	15	COORD	_	_
21	the	_	DT	_	_	22	NMOD	_	_
22	nature	_	NN	_	_	20	CONJ	_	_
23	of	_	IN	_	_	22	NMOD	_	_
24	its	_	PRP$	_	_	26	NMOD	_	_
25	strategic	_	JJ	_	_	26	NMOD	_	_
26	plan	_	NN	_	_	23	PMOD	_	_
27	.	_	.	_	_	3	P	_	_

1	At	_	IN	_	_	11	TMP	_	_
2	the	_	DT	_	_	3	NMOD	_	_
3	end	_	NN	_	_	1	PMOD	_	_
4	of	_	IN	_	_	3	NMOD	_	_
5	this	_	DT	_	_	6	NMOD	_	_
6	period	_	NN	_	_	4	PMOD	_	_
7	,	_	,	_	_	11	P	_	_
8	the	_	DT	_	_	10	NMOD	_	_
9	poison	_	NN	_	_	10	NMOD	_	_
10	pill	_	NN	_	_	11	SBJ	_	_
11	would	_	MD	_	_	0	ROOT	_	_
12	be	_	VB	_	_	11	VC	_	_
13	eliminated	_	VBN	_	_	12	VC	_	_
14	automatically	_	RB	_	_	13	MNR	_	_
15	,	_	,	_	_	13	P	_	_
16	unless	_	IN	_	_	13	ADV	_	_
17	a	_	DT	_	_	20	NMOD	_	_
18	new	_	JJ	_	_	20	NMOD	_	_
19	poison	_	NN	_	_	20	NMOD	_	_
20	pill	_	NN	_	_	21	SBJ	_	_
21	were	_	VBD	_	_	16	SUB	_	_
22	approved	_	VBN	_	_	21	VC	_	_
23	by	_	IN	_	_	22	LGS	_	_
24	the	_	DT	_	_	26	NMOD	_	_
25	then-current	_	JJ	_	_	26	NMOD	_	_
26	shareholders	_	NNS	_	_	23	PMOD	_	_
27	,	_	,	_	_	26	P	_	_
28	who	_	WP	_	_	29	SBJ	_	_
29	would	_	MD	_	_	26	NMOD	_	_
30	have	_	VB	_	_	29	VC	_	_
31	an	_	DT	_	_	32	NMOD	_	_
32	opportunity	_	NN	_	_	30	OBJ	_	_
33	to	_	TO	_	_	32	NMOD	_	_
34	evaluate	_	VB	_	_	33	IM	_	_
35	the	_	DT	_	_	36	NMOD	_	_
36	corporation	_	NN	_	_	38	NMOD	_	_
37	's	_	POS	_	_	36	SUFFIX	_	_
38	strategy	_	NN	_	_	34	OBJ	_	_
39	and	_	CC	_	_	38	COORD	_	_
40	management	_	NN	_	_	41	NMOD	_	_
41	team	_	NN	_	_	39	CONJ	_	_
42	at	_	IN	_	_	30	TMP	_	_
43	that	_	DT	_	_	44	NMOD	_	_
44	time	_	NN	_	_	42	PMOD	_	_
45	.	_	.	_	_	11	P	_	_

1	One	_	CD	_	_	3	NMOD	_	_
2	rare	_	JJ	_	_	3	NMOD	_	_
3	example	_	NN	_	_	9	SBJ	_	_
4	of	_	IN	_	_	3	NMOD	_	_
5	a	_	DT	_	_	8	NMOD	_	_
6	time-limited	_	JJ	_	_	8	NMOD	_	_
7	poison	_	NN	_	_	8	NMOD	_	_
8	pill	_	NN	_	_	4	PMOD	_	_
9	is	_	VBZ	_	_	0	ROOT	_	_
10	the	_	DT	_	_	13	NMOD	_	_
11	shareholder	_	NN	_	_	13	NMOD	_	_
12	rights	_	NNS	_	_	13	NMOD	_	_
13	plan	_	NN	_	_	9	PRD	_	_
14	adopted	_	VBN	_	_	13	APPO	_	_
15	by	_	IN	_	_	14	LGS	_	_
16	Pennzoil	_	NNP	_	_	15	PMOD	_	_
17	last	_	JJ	_	_	18	NMOD	_	_
18	year	_	NN	_	_	14	TMP	_	_
19	after	_	IN	_	_	14	TMP	_	_
20	it	_	PRP	_	_	21	SBJ	_	_
21	received	_	VBD	_	_	19	SUB	_	_
22	a	_	DT	_	_	25	NMOD	_	_
23	huge	_	JJ	_	_	25	NMOD	_	_
24	litigation	_	NN	_	_	25	NMOD	_	_
25	settlement	_	NN	_	_	21	OBJ	_	_
26	from	_	IN	_	_	21	ADV	_	_
27	Texaco	_	NNP	_	_	26	PMOD	_	_
28	.	_	.	_	_	9	P	_	_

1	Pennzoil	_	NNP	_	_	4	NMOD	_	_
2	's	_	POS	_	_	1	SUFFIX	_	_
3	poison	_	NN	_	_	4	NMOD	_	_
4	pill	_	NN	_	_	5	SBJ	_	_
5	covers	_	VBZ	_	_	0	ROOT	_	_
6	five	_	CD	_	_	7	NMOD	_	_
7	years	_	NNS	_	_	5	OBJ	_	_
8	in	_	IN	_	_	5	PRP	_	_
9	order	_	NN	_	_	8	DEP	_	_
10	to	_	TO	_	_	8	SUB	_	_
11	give	_	VB	_	_	10	IM	_	_
12	current	_	JJ	_	_	13	NMOD	_	_
13	management	_	NN	_	_	11	OBJ	_	_
14	enough	_	JJ	_	_	15	NMOD	_	_
15	time	_	NN	_	_	11	OBJ	_	_
16	to	_	TO	_	_	15	NMOD	_	_
17	put	_	VB	_	_	16	IM	_	_
18	these	_	DT	_	_	19	NMOD	_	_
19	proceeds	_	NNS	_	_	17	OBJ	_	_
20	to	_	TO	_	_	17	ADV	_	_
21	work	_	VB	_	_	20	PMOD	_	_
22	in	_	IN	_	_	17	MNR	_	_
23	a	_	DT	_	_	25	NMOD	_	_
24	prudent	_	JJ	_	_	25	NMOD	_	_
25	manner	_	NN	_	_	22	PMOD	_	_
26	.	_	.	_	_	5	P	_	_

1	Another	_	DT	_	_	3	NMOD	_	_
2	interesting	_	JJ	_	_	3	NMOD	_	_
3	example	_	NN	_	_	4	SBJ	_	_
4	is	_	VBZ	_	_	0	ROOT	_	_
5	the	_	DT	_	_	7	NMOD	_	_
6	poison	_	NN	_	_	7	NMOD	_	_
7	pill	_	NN	_	_	4	PRD	_	_
8	adopted	_	VBN	_	_	7	APPO	_	_
9	recently	_	RB	_	_	8	TMP	_	_
10	by	_	IN	_	_	8	LGS	_	_
11	Pittsburgh-based	_	JJ	_	_	13	NMOD	_	_
12	National	_	NNP	_	_	13	NAME	_	_
13	Intergroup	_	NNP	_	_	10	PMOD	_	_
14	Inc.	_	NNP	_	_	13	POSTHON	_	_
15	,	_	,	_	_	13	P	_	_
16	a	_	DT	_	_	19	NMOD	_	_
17	diversified	_	JJ	_	_	19	NMOD	_	_
18	holding	_	VBG	_	_	19	NMOD	_	_
19	company	_	NN	_	_	13	APPO	_	_
20	.	_	.	_	_	4	P	_	_

1	The	_	DT	_	_	6	NMOD	_	_
2	State	_	NNP	_	_	6	NMOD	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	Wisconsin	_	NNP	_	_	3	PMOD	_	_
5	Investment	_	NNP	_	_	6	NAME	_	_
6	Board	_	NNP	_	_	20	SBJ	_	_
7	,	_	,	_	_	6	P	_	_
8	which	_	WDT	_	_	9	SBJ	_	_
9	owned	_	VBD	_	_	6	NMOD	_	_
10	about	_	IN	_	_	11	DEP	_	_
11	7	_	CD	_	_	12	NMOD	_	_
12	%	_	NN	_	_	9	OBJ	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	the	_	DT	_	_	15	NMOD	_	_
15	company	_	NN	_	_	18	NMOD	_	_
16	's	_	POS	_	_	15	SUFFIX	_	_
17	voting	_	NN	_	_	18	NMOD	_	_
18	stock	_	NN	_	_	13	PMOD	_	_
19	,	_	,	_	_	6	P	_	_
20	worked	_	VBD	_	_	0	ROOT	_	_
21	with	_	IN	_	_	20	ADV	_	_
22	management	_	NN	_	_	21	PMOD	_	_
23	to	_	TO	_	_	20	PRP	_	_
24	devise	_	VB	_	_	23	IM	_	_
25	a	_	DT	_	_	28	NMOD	_	_
26	time-limited	_	JJ	_	_	28	NMOD	_	_
27	poison	_	NN	_	_	28	NMOD	_	_
28	pill	_	NN	_	_	24	OBJ	_	_
29	.	_	.	_	_	20	P	_	_

1	This	_	DT	_	_	2	NMOD	_	_
2	pill	_	NN	_	_	4	SBJ	_	_
3	automatically	_	RB	_	_	4	ADV	_	_
4	expires	_	VBZ	_	_	0	ROOT	_	_
5	after	_	IN	_	_	4	TMP	_	_
6	three	_	CD	_	_	7	NMOD	_	_
7	years	_	NNS	_	_	5	PMOD	_	_
8	unless	_	IN	_	_	4	ADV	_	_
9	continued	_	VBN	_	_	8	SUB	_	_
10	by	_	IN	_	_	9	LGS	_	_
11	a	_	DT	_	_	12	NMOD	_	_
12	vote	_	NN	_	_	10	PMOD	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	the	_	DT	_	_	15	NMOD	_	_
15	shareholders	_	NNS	_	_	13	PMOD	_	_
16	.	_	.	_	_	4	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	attitude	_	NN	_	_	8	SBJ	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	the	_	DT	_	_	7	NMOD	_	_
5	Wisconsin	_	NNP	_	_	7	NAME	_	_
6	Investment	_	NNP	_	_	7	NAME	_	_
7	Board	_	NNP	_	_	3	PMOD	_	_
8	reflects	_	VBZ	_	_	0	ROOT	_	_
9	a	_	DT	_	_	11	NMOD	_	_
10	growing	_	VBG	_	_	11	NMOD	_	_
11	receptivity	_	NN	_	_	8	OBJ	_	_
12	to	_	TO	_	_	11	NMOD	_	_
13	time-limited	_	JJ	_	_	15	NMOD	_	_
14	poison	_	NN	_	_	15	NMOD	_	_
15	pills	_	NNS	_	_	12	PMOD	_	_
16	on	_	IN	_	_	11	NMOD	_	_
17	the	_	DT	_	_	18	NMOD	_	_
18	part	_	NN	_	_	16	PMOD	_	_
19	of	_	IN	_	_	18	NMOD	_	_
20	institutional	_	JJ	_	_	21	NMOD	_	_
21	investors	_	NNS	_	_	19	PMOD	_	_
22	,	_	,	_	_	8	P	_	_
23	as	_	IN	_	_	8	ADV	_	_
24	shown	_	VBN	_	_	23	SUB	_	_
25	by	_	IN	_	_	24	LGS	_	_
26	the	_	DT	_	_	27	NMOD	_	_
27	discussions	_	NNS	_	_	25	PMOD	_	_
28	at	_	IN	_	_	27	LOC	_	_
29	recent	_	JJ	_	_	30	NMOD	_	_
30	meetings	_	NNS	_	_	28	PMOD	_	_
31	of	_	IN	_	_	30	NMOD	_	_
32	the	_	DT	_	_	33	NMOD	_	_
33	Council	_	NNP	_	_	31	PMOD	_	_
34	of	_	IN	_	_	33	NMOD	_	_
35	Institutional	_	NNP	_	_	36	NAME	_	_
36	Investors	_	NNPS	_	_	34	PMOD	_	_
37	and	_	CC	_	_	27	COORD	_	_
38	my	_	PRP$	_	_	40	NMOD	_	_
39	informal	_	JJ	_	_	40	NMOD	_	_
40	survey	_	NN	_	_	37	CONJ	_	_
41	of	_	IN	_	_	40	NMOD	_	_
42	several	_	JJ	_	_	44	NMOD	_	_
43	retirement	_	NN	_	_	44	NMOD	_	_
44	plans	_	NNS	_	_	41	PMOD	_	_
45	with	_	IN	_	_	44	NMOD	_	_
46	large	_	JJ	_	_	48	NMOD	_	_
47	stock	_	NN	_	_	48	NMOD	_	_
48	positions	_	NNS	_	_	45	PMOD	_	_
49	.	_	.	_	_	8	P	_	_

1	More	_	RBR	_	_	2	AMOD	_	_
2	widespread	_	JJ	_	_	4	NMOD	_	_
3	time	_	NN	_	_	4	NMOD	_	_
4	limits	_	NNS	_	_	8	SBJ	_	_
5	on	_	IN	_	_	4	NMOD	_	_
6	poison	_	NN	_	_	7	NMOD	_	_
7	pills	_	NNS	_	_	5	PMOD	_	_
8	would	_	MD	_	_	0	ROOT	_	_
9	allow	_	VB	_	_	8	VC	_	_
10	shareholders	_	NNS	_	_	9	OBJ	_	_
11	to	_	TO	_	_	9	OPRD	_	_
12	evaluate	_	VB	_	_	11	IM	_	_
13	a	_	DT	_	_	16	NMOD	_	_
14	specific	_	JJ	_	_	16	NMOD	_	_
15	poison	_	NN	_	_	16	NMOD	_	_
16	pill	_	NN	_	_	12	OBJ	_	_
17	within	_	IN	_	_	12	ADV	_	_
18	the	_	DT	_	_	19	NMOD	_	_
19	context	_	NN	_	_	17	PMOD	_	_
20	of	_	IN	_	_	19	NMOD	_	_
21	a	_	DT	_	_	24	NMOD	_	_
22	specific	_	JJ	_	_	24	NMOD	_	_
23	management	_	NN	_	_	24	NMOD	_	_
24	team	_	NN	_	_	26	NMOD	_	_
25	's	_	POS	_	_	24	SUFFIX	_	_
26	strategy	_	NN	_	_	20	PMOD	_	_
27	.	_	.	_	_	8	P	_	_

1	Such	_	JJ	_	_	3	NMOD	_	_
2	concrete	_	JJ	_	_	3	NMOD	_	_
3	analysis	_	NN	_	_	4	SBJ	_	_
4	is	_	VBZ	_	_	0	ROOT	_	_
5	likely	_	JJ	_	_	4	PRD	_	_
6	to	_	TO	_	_	5	AMOD	_	_
7	lead	_	VB	_	_	6	IM	_	_
8	to	_	TO	_	_	7	DIR	_	_
9	more	_	RBR	_	_	10	AMOD	_	_
10	fruitful	_	JJ	_	_	11	NMOD	_	_
11	dialogue	_	NN	_	_	8	PMOD	_	_
12	between	_	IN	_	_	11	NMOD	_	_
13	management	_	NN	_	_	12	PMOD	_	_
14	and	_	CC	_	_	13	COORD	_	_
15	shareholders	_	NNS	_	_	14	CONJ	_	_
16	than	_	IN	_	_	11	NMOD	_	_
17	the	_	DT	_	_	19	NMOD	_	_
18	abstract	_	JJ	_	_	19	NMOD	_	_
19	debate	_	NN	_	_	16	PMOD	_	_
20	about	_	IN	_	_	19	NMOD	_	_
21	poison	_	NN	_	_	22	NMOD	_	_
22	pills	_	NNS	_	_	20	PMOD	_	_
23	.	_	.	_	_	4	P	_	_

1	Mr.	_	NNP	_	_	2	TITLE	_	_
2	Pozen	_	NNP	_	_	3	SBJ	_	_
3	is	_	VBZ	_	_	0	ROOT	_	_
4	the	_	DT	_	_	6	NMOD	_	_
5	general	_	JJ	_	_	6	NMOD	_	_
6	counsel	_	NN	_	_	3	PRD	_	_
7	and	_	CC	_	_	6	COORD	_	_
8	a	_	DT	_	_	10	NMOD	_	_
9	managing	_	VBG	_	_	10	NMOD	_	_
10	director	_	NN	_	_	7	CONJ	_	_
11	of	_	IN	_	_	6	NMOD	_	_
12	Fidelity	_	NNP	_	_	13	NAME	_	_
13	Investments	_	NNPS	_	_	11	PMOD	_	_
14	in	_	IN	_	_	13	LOC	_	_
15	Boston	_	NNP	_	_	14	PMOD	_	_
16	.	_	.	_	_	3	P	_	_

